Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker Corporation (Nasdaq: BRKR) launched two new timsTOF instruments at its virtual 4D-Proteomics™ eXceed Symposium. The timsTOF trueSCP enhances quantitative single-cell proteomics, achieving 1,500 proteins per cell, while the timsTOF Pro 2 boasts advanced capabilities for unbiased 4D-Proteomics, identifying over 6,000 proteins and 60,000 unique peptides. New PaSER software supports real-time peptide sequencing and CCS-enabled bioinformatics, improving identification accuracy. CEO Frank H. Laukien emphasized the significance of these innovations for advancing cancer detection and personalized therapy.
A recent clinical research collaboration has explored transient and persistent systemic changes in COVID-19 patient blood samples, revealing biochemical abnormalities related to long COVID symptoms that can persist for months. Using an innovative assay platform of NMR spectroscopy and mass spectrometry, the study identified that over 57% of mildly affected COVID-19 patients experience ongoing health issues three months post-infection. The research emphasizes the need for longitudinal studies to understand future health risks better.
Bruker Corporation (Nasdaq: BRKR) announced a new share repurchase authorization for up to $500 million over two years, starting May 13, 2021. This initiative reflects the company's confidence in its long-term prospects. The repurchase may occur through various methods and can be suspended at any time. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, set for June 18, 2021, to stockholders of record as of June 1, 2021.
Bruker Corporation (Nasdaq: BRKR) has authorized a new share repurchase plan of up to $500 million over two years starting May 13, 2021. This decision reflects the company's confidence in its long-term prospects. Shares may be repurchased via open market transactions or trading plans under Rule 10b5-1. Additionally, Bruker declared a quarterly cash dividend of $0.04 per share, payable on June 18, 2021, to stockholders of record as of June 1, 2021.
Bruker Corporation has announced that its 1H-NMR spectroscopy has been officially incorporated by the International Organization of Vine and Wine (OIV) for quantifying key wine parameters such as glucose and acidity. This advancement allows for simultaneous and accurate measurement of 53 compounds in a single automated process, addressing the demand for authenticity in wine supply chains. Bruker's NMR Wine-Profiling™ 4.0 enhances supply chain verification and counters fraud, marking a significant innovation in the wine industry.
Bruker Corporation (Nasdaq: BRKR) announced its participation in three upcoming virtual healthcare conferences. The events include the BofA Securities 2021 Health Care Conference on May 11, 2021, the UBS Global Healthcare Virtual Conference on May 24, 2021, and the Jefferies Virtual Healthcare Conference on June 2, 2021. Key executives, including Frank Laukien and Mark Munch, will present. Live webcasts and replays will be accessible on the Investor Relations section of Bruker's website for 30 days post-event.
Bruker Corporation (Nasdaq: BRKR) reported first-quarter revenues of $554.7 million, up 30.8% year-over-year from $424.0 million. Organic growth was 23.8%, with foreign currency effects contributing 6.2%. Bruker Scientific Instruments saw revenues rise 32.7% to $506.2 million, while Bruker Energy & Supercon Technologies increased 13.4% to $52.4 million. GAAP operating income surged to $89.1 million with a margin of 16.1%, and EPS reached $0.37. The company raised its FY 2021 guidance, expecting 14%-16% revenue growth and non-GAAP EPS of $1.82 to $1.87.
Bruker Corporation (Nasdaq: BRKR) reported preliminary revenue for Q1 2021 between $549 million and $554 million, reflecting 30% to 31% growth year-over-year. Excluding effects from currency fluctuations and acquisitions, the non-GAAP organic revenue growth is estimated at 22% to 23%, exceeding earlier forecasts of 15%. Revenue growth was attributed to strong performance in all three Bruker Scientific Instrument groups, including notable sales of GHz-class NMR systems. Full financial results are expected on May 5, 2021.
Bruker Corporation (Nasdaq: BRKR) announced the addition of a 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometer at Forschungszentrum Juelich (FZJ), Germany. This new technology enhances research capabilities in neurodegenerative diseases, particularly Alzheimer's, by improving the structural analysis of protein-ligand interactions. The installation boosts the sensitivity and resolution of NMR studies, facilitating advancements in antibiotic development and understanding of molecular mechanisms. Initial results show promising progress in obtaining spectra from valuable disease research samples.
Bruker Corporation (Nasdaq: BRKR) has launched several magnetic resonance systems, including the Fourier™ 80, a high-performance 80 MHz FT-NMR benchtop spectrometer, aimed at enhancing accessibility for pharma, chemical, and food research. The AvanceCore 400, a cost-effective 400 MHz NMR system, is also introduced to broaden accessibility. Additionally, the Magnettech ESR 5000 benchtop EPR system offers compact performance for various applications. These innovations are designed to improve data quality and increase throughput in research labs.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
